Skip to main content

Advertisement

SpringerLink
Log in

Small Round Blue Cell Sarcoma Other Than Ewing Sarcoma: What Should an Oncologist Know?

  • Sarcoma (SH Okuno, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The diagnosis of round cell sarcomas has changed rapidly over the last decade, causing much diagnostic confusion for pathologists and oncologists. The advances in diagnosis are largely due to the advent of next-generation sequencing techniques, which allowed the recognition of novel gene fusions in round cell sarcomas. The new 5th edition of the WHO Classification of Tumors of Soft Tissue and Bone recognizes four subgroups of undifferentiated round cell sarcomas: Ewing sarcoma, CIC-rearranged sarcomas, BCOR-altered sarcomas, and sarcomas with EWSR1-non-ETS fusions, in addition to desmoplastic small round cell tumor. This classification is based on a variety of publications showing that each of these molecular subtypes has unique clinical and prognostic characteristics distinct from Ewing sarcoma, therefore supporting the validity of recognizing these as discrete diagnostic entities. Despite our improved ability to diagnose these new round cell sarcomas, there remains confusion on how best to identify and treat these tumors. However, several key clinicopathologic features can point the physician toward the correct diagnosis. The goal of the following article is to emphasize the key clinical, pathologic, molecular, and prognostic differences between Ewing sarcoma and these non-Ewing round cell malignancies to improve recognition of these rare diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Antonescu CR. Round cell sarcomas beyond Ewing: emerging entitites. Histopathology 2014;64.

  2. •Fletcher CDE. WHO classification of tumours editorial board: soft tissue and bone tumors, 5th edition, vol 3. International Agency for Research on Cancer, Lyon; 2020. New WHO classification of soft tissue tumors includes molecular characterization of rare subgroups.

  3. Esiashvili GMN, Marcus RB. Changes in incidence and survival of Ewing sarcoma patients of the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008;30:425–30.

    Article  Google Scholar 

  4. A.L. Folpe, Goldblum JR, Rubin BP Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol. 2005;29.

  5. M.I. Llombart-Bosch A, Navarro S et al, Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support., Virchows Arch, 455 (2009).

  6. Tirode SDF, Ma X, Parker M, Le Deley MC, Bahrami A, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014;4:1342–53.

    Article  CAS  Google Scholar 

  7. Fletcher C, Hung YP, Hornick JL. Evaluation of NKX2.2 expression in round cell sarcomas and other tumors with EWSR1 rearrangement: imperfect specificity for Ewing sarcoma. Mod Pathol. 2016;29:370–80.

    Article  Google Scholar 

  8. Rooper BJLM. Soft tissue special issue: adamantinoma-like Ewing sarcoma of the head and neck: a practical review of a challenging emerging entity. Head Neck Pathol, 2020.

  9. Van Mater D, Wagner L. Management of recurrent Ewing sarcoma: challenges and approaches. Onco Targets Ther. 2019;12:2279–88.

    Article  Google Scholar 

  10. Gorlick JKR, Adamson PC. Dose intensification improves outcome of Ewing sarcoma. J Clin Oncol, 2018.

  11. Garcia-Filion P, Lettieri CK, Hingorani P. Incidence and outcomes of desmoplastic small round cell tumor: results from the surveillance. Epidemiology and End Results Database, J Cancer Epidemiology. 2014;2014:1–5.

    Google Scholar 

  12. Ladanyi M, Gerald WL, de Alava E, et al. Clinical, pathologic and molecular spectrum of tumors associated with t(111;22)(p13;q12): desmoplastic small round cell tumor and its variants. J Clin Oncol. 1998;1998:9.

    Google Scholar 

  13. Kabbara N, Philippe-Chomette P, Andre N, et al. Desmoplastic small round cell tumors with EWS-WT1 fusion transcript in children and young adults. Pediatr Blood Cancer. 2012;58:891–7.

    Article  Google Scholar 

  14. Perlman E, Wang LL, Vujanic GM, et al. Desmoplastic small round cell tumor of the kidney in childhood. Am J Surg Pathol. 2007;31:576–84.

    Article  Google Scholar 

  15. Hayes-Jordan A, La Quaglia MP, Modak S. Management of desmoplastic small round cell tumor. Semin Pediatr Surg. 2016;25:299–304.

    Article  Google Scholar 

  16. •• YC OAK, Sung YS, Zhang L, Fujisawa Y, Lee JC, Wexler L, et al. BCOR-CCNB3 fusion positive sarcomas: a clinicopathologic and molecular analysis of 36 cases with comparison to morphologic spectrum and clinical behavior of other round cell sarcomas. Am J Surg Pathol. 2018;42:604–15. BCOR altered tumors represent a distinct clinicopathologic entity in comparison to Ewing or other undifferentiated sarcomas.

    Google Scholar 

  17. Kao Y, Argani P, Zhang L, et al. Primary renal sarcomas with BCOR-CCNB3 gene fusion: a report of 2 cases showing histologic overlap with clear cell sarcoma of kidney, suggesting further link between BCOR-related sarcomas of the kidney and soft tissues. Am J Surg Pathol. 2017;2017:12.

    Google Scholar 

  18. Sung Y, Kao YC, Zhang L, et al. BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities. Am J Surg Pathol. 2016;40:1670–8.

    Article  Google Scholar 

  19. Ninfo V, Alaggio R, Rosolen A, Coffin CM. Primitive myxoid mesenchymal tumor of infancy: a clinicopathologic report of 6 cases. Am J Surg Pathol. 2006;30:388–94.

    Article  Google Scholar 

  20. Chiang S, Momeni-Boroujeni A. Uterine mesenchymal tumors: recent advances. Histopathology. 2020;76:64–75.

    Article  Google Scholar 

  21. Vega VJ, Ferris SP, Aboian M, Lee JC, Van Ziffle J, Onodera C, et al. High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication - a comprehensive clinical, radiographic, pathologic and genomic analysis. Brain Pathol. 2020;30:46–62.

    Article  Google Scholar 

  22. Mankhuzy NP, Kumar C, Heider A, Koschmamn C, Mody RJ et al. BCOR alterations in pediatric and adolescent young adult patients with sarcomas and high grade glial malignancies., JCO Precis Oncol 2019.

  23. Kumar V, Peters TL, Polikepahad S, Lin FY, Sarabia SF, Liang Y, et al. BCOR-CCNB3 fusions are frequent in undifferentiated sarcomas of male children. Mod Pathol. 2014;28:575–86.

    PubMed  PubMed Central  Google Scholar 

  24. Zhang L, Specht K, Sung YS, et al. Novel BCOR-MAML3 and ZC3H7B-BCOR gene fusions in undifferentiated small blue round cell sarcomas. Am J Surg Pathol. 2016;40:433–42.

    Article  Google Scholar 

  25. Zreik R. Malik F, Hedges DJ, Nakitandwe J, Lee S, Ward RA, McCarville B, Pappo A, Bahrami A., Primary bone sarcoma with BCOR internal tandem duplication. Virchows Arch 2020.

  26. Felisiak-Golabek A, Miettinen M, Luina Contreras A, Glod J, Kaplan RN, Killian JK, et al. New fusion sarcomas: histopathology and clinical significance of selected entitites. Human Pathology. 2019;86:57–65.

    Article  Google Scholar 

  27. Pillay K, Pietro Aldera A. Clear cell sarcoma of the kidney. Arch Pathol Lab Med. 2019;144:119–23.

    PubMed  Google Scholar 

  28. Cramer SL, Ali S, Bradley JA, Kim HK, Pressey JG, et al. Myxoid mesenchymal tumor of infancy with BCOR internal tandem duplication. J Natl Compr Canc Netw. 2017;15:868–71.

    Article  Google Scholar 

  29. •• Antonescu CR, Owosho AA, Zhang L, et al. Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases. Am J Surg Pathol. 2017;41:941–9. CIC-rearranged sarcomas represent a distinct clinicopathology entity in comparison to Ewing sarcoma, and have a worse prognosis and response to traditional Ewing chemotherapy.

    Article  Google Scholar 

  30. Navarro L. Machado I, Pellin A, Navarro S, Agaimy A, Tardio JC et al, Defining Ewing and Ewing-like small round cell tumors: the need for molecular techniques in their categorization and differential diagnosis. A study of 200 cases. Ann Diagn Pathol 2016;22.

  31. Sung Y, Specht K, Zhang L, Richter GH, Fletcher CD, Antonescu CR. Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities. Genes Chromosomes Cancer. 2014;53:622–33.

    Article  Google Scholar 

  32. Pissaloux D. Le Loarer F, Watson S et al, Clinicaopathologic features of CIC-NUTM1 sarcomas, a new molecular variant of the family of CIC-fused sarcomas, Am J Surg Pathol 2018.

  33. Yoshida A, Goto K, Kodaira M, Kobayashi E, Kawamoto H, Mori T, et al. CIC-rearranged sarcomas: a study of 20 cases and comparisons with Ewing sarcomas. Am J Surg Pathol. 2016;40:313–23.

    Article  Google Scholar 

  34. Sung Y, Kao YC, Chen CL, et al. ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with CIC gene rearrangements. Genes Chromosomes Cancer. 2017;56:501–10.

    Article  Google Scholar 

  35. Marusic Z. Ko JS, Azzato EM, Farkas DH, Van Arnam J, Seiwerth S, Fritchie K, Patel RM, Rubin BP, Billing SD. Superficial sarcomas with CIC rearrangement are aggressive neoplasms: a series of eight cases. J Cut Pathol 2020.

  36. Nielsen G, Diaz-Perez JA, Antonescu C, Taylor MS, Lozano-Calderon SA, Rosenberg AE. EWSR1/FUS-NFATC2 rearranged round cell sarcomas: clinicopathological series of 4 cases and literature review. Hum Pathol. 2019;90:45–53.

    Article  Google Scholar 

  37. Thomas D, Wang GY, Davis JL, et al. EWSR1-NFATC2 translocation-associated sarcoma: clinicopathologic findings in a rare aggressive primary bone or soft tissue tumor. Am J Surg Pathol 2019.

  38. Sabnis A, Cohen JN, Krings G, et al. EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid and round cell morphology and abundant stroma: a case report and review of the literature. Human Pathology. 2018;81:281–90.

    Article  Google Scholar 

  39. Sumegi J, Bridge JA, Druta M, Bui MM, Herson-Jackson E, Linos K, et al. Clinical, patholgoical and genomic features of EWSR1-PATZ1 fusion sarcoma. Mod Pathol. 2019;32:1593–604.

    Article  Google Scholar 

  40. Taylor M, Cougule A, Nardi V, et al. Spindle and round cell sarcoma with EWSR1-PATZ1 gene fusion: a sarcoma with polyphenotypic differentiation. Am J Surg Pathol. 2019;43:220–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Oregon Health & Science University, Portland, OR, 97239, USA

    Jessica L. Davis MD

  2. Department of Laboratories, Seattle Children’s Hospital, Seattle, WA, 98105, USA

    Erin R. Rudzinski MD

Authors
  1. Jessica L. Davis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erin R. Rudzinski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erin R. Rudzinski MD.

Ethics declarations

Conflict of interest

Jessica L Davis declares that she has no conflict of interest.

Erin R Rudzinski declares that she has no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Sarcoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davis, J.L., Rudzinski, E.R. Small Round Blue Cell Sarcoma Other Than Ewing Sarcoma: What Should an Oncologist Know?. Curr. Treat. Options in Oncol. 21, 90 (2020). https://doi.org/10.1007/s11864-020-00785-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-020-00785-1

Keywords

Search

Navigation